These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 28302411

  • 1. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J.
    Vaccine; 2017 Apr 04; 35(15):1856-1864. PubMed ID: 28302411
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, Leong J.
    Vaccine; 2017 May 09; 35(20):2745-2752. PubMed ID: 28390934
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2015 Feb 25; 33(9):1151-9. PubMed ID: 25613721
    [Abstract] [Full Text] [Related]

  • 5. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T.
    Hum Vaccin Immunother; 2016 Dec 15; 12(12):3072-3078. PubMed ID: 27565435
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, QHD00013 Study Group.
    Vaccine; 2019 Sep 16; 37(39):5825-5834. PubMed ID: 31431411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, Kowalska E, Van Damme P, Salamand C, Pepin S.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):596-608. PubMed ID: 28968138
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA, Saway W, Gouaux J, Baron M, Baker J, Denis M, Jordanov E, Landolfi V, Yau E.
    Vaccine; 2015 Dec 16; 33(51):7188-7193. PubMed ID: 26555348
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS, Noh JY, Song JY, Cheong HJ, Wie SH, Lee JS, Lee J, Kim SW, Jeong HW, Jung SI, Kim YS, Woo HJ, Kim KH, Kim H, Kim WJ.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1653-1660. PubMed ID: 28406746
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
    Chu K, Xu K, Tang R, Tian X, Hu J, Yang T, Li C, Hu Y, Zeng G.
    Vaccine; 2020 Aug 18; 38(37):5940-5946. PubMed ID: 32732142
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL.
    Vaccine; 2017 Nov 01; 35(46):6321-6328. PubMed ID: 28987445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.